Advertisement

Transforming growth factor-ß: localization and possible functional roles in cardiac myocytes

  • Anita B. Roberts
  • Michael B. Sporn
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 147)

Abstract

Recently it has become appreciated that the myocardium produces several growth factors (cytokines) and that their expression is highly regulated not only in development but also in injury and disease [1]. One of these cytokines, transforming growth factor-ß (TGF-ß), a dimeric, multifunctional peptide [2], is expressed at high levels in the heart during both embryonic and adult life [3,4]. In this brief review, we will discuss the results of investigations directed at elucidating the role of TGF-ß in the heart with emphasis on its localization in the adult myocardium, its possible function in maintaining the rhythmic, contractile nature of cardiac tissue, and its role in response of the heart to injury and to ischemia.

Keywords

Nitric Oxide Cardiac Myocytes Beat Rate Beating Rate Neonatal Cardiac Myocytes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schneider MD, Parker TD. Cardiac growth factors. Rec Prog Growth Factor Res 1991; 3:1–26.CrossRefGoogle Scholar
  2. 2.
    Roberts AB, Sporn MB. The transforming growth factors-ß, In: Sporn MB, Roberts AB editors: Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors. Springer-Verlag, Berlin, 1990; 95: 419–472.CrossRefGoogle Scholar
  3. 3.
    Thompson NL, Bazoberry F, Speir EH, et al. Transforming growth factor-ßl in acute myocardial infarction in rats. Growth Factors 1988; 1: 91–99.PubMedCrossRefGoogle Scholar
  4. 4.
    Thompson NL, Flanders KC, Smith JM, et al. Expression of transforming growth factor-ßl in specific cells and tissues of adult and neonatal mice. J Cell Biol 1989; 108: 661–669.PubMedCrossRefGoogle Scholar
  5. 5.
    Roberts AB, Anzano MA, Lamb LC, et al. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A 1981; 78: 5339–5343.PubMedCrossRefGoogle Scholar
  6. 6.
    Heine UI, Burmester JK, Flanders KC, et al. Localization of transforming growth factor-ßl in mitochondria of murine heart and liver. Cell Regulation 1991; 2: 467–477.PubMedGoogle Scholar
  7. 7.
    Dahlback B, Hildebrand B, Linse S. Novel type of very high affinity calcium-binding sites in ß-hydroxy-asparagine-containing epidermal growth factor-like domains in vitamin K-dependent proteins. J Biol Chem 1990; 265: 18481–18489.PubMedGoogle Scholar
  8. 8.
    Kansaki T, Olofsson A, Moren A, et al. TGF-ßl binding protein: a component of the large latent complex of TGF-ßl with multiple repeat sequences. Cell 1990; 61: 1051–1061.CrossRefGoogle Scholar
  9. 9.
    Qian SW, Kondaiah P, Casscells W, et al. A second messenger RNA species of transforming growth factor-ßl in infarcted rat heart. Cell Regulation 1991; 2: 241–249.PubMedGoogle Scholar
  10. 10.
    Kim S-J, Kim K-Y, Wakefield LM, et al: Post-transcriptional regulation of the human transforming growth factor-ßl gene. J Biol Chem 1992; 267: 13702–13707.PubMedGoogle Scholar
  11. 11.
    Lefer AM, Tsao P, Aoki N, et al. Mediation of cardioprotection by transforming growth factor-ß. Science 1990; 249: 61–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Lefer AM. Mechanisms of the protective effects of transforming growth factor-ß in reperfusion injury. Biochem Pharmacol 1991 42: 1323–1327.PubMedCrossRefGoogle Scholar
  13. 13.
    Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-ß. Science 1988; 242: 97–99.PubMedCrossRefGoogle Scholar
  14. 14.
    Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-ß (TGF-ß). Growth Factors 1992; in press.Google Scholar
  15. 15.
    Roberts AB, Roche NS, Winokur TS, et al. Role of TGF-ß in maintenance of function of cultured cardiac myocytes: autocrine action and reversal of damaging effects of interleukin-1. J Clin Invest 1992; in press.Google Scholar
  16. 16.
    Gulick T, Chung MK, Pieper SJ, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte ß-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989; 86: 6753–6757.PubMedCrossRefGoogle Scholar
  17. 17.
    Heino J, Heinonen T. Interleukin-1 ß prevents the stimulatory effect of transforming growth factor-ß on collagen gene expression in human skin fibroblasts. Biochem J 1990; 271: 827–830.PubMedGoogle Scholar
  18. 18.
    Musso T, Espinoza-Delgado I, Pulkki K, et al. Transforming growth factor ß downregulates interleukin-1 (IL-l)-induced IL-6 production by human monocytes. Blood 1990; 76: 2466–2469.PubMedGoogle Scholar
  19. 19.
    Pfeilschifter J, Pignat W, Leighton J, et al. Transforming growth factor ß2 differentially modulates interleukin-1 ß and tumour-necrosis-factor-α-stimulated phospholipase A2 and prostaglandin E2 synthesis in rat renal mesangial cells. Biochem J 1990; 270: 269–271.PubMedGoogle Scholar
  20. 20.
    Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051–3064.PubMedGoogle Scholar
  21. 21.
    Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387–389.PubMedCrossRefGoogle Scholar
  22. 22.
    Matheis G, Sherman MP, Buckberg GD, et al. Role of L-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol 1992; 262: H616–H620.PubMedGoogle Scholar
  23. 23.
    Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992; 105: 575–580.PubMedCrossRefGoogle Scholar
  24. 24.
    Roberts AB, Vodovotz Y, Roche NS, et al. Role of nitric oxide in antagonistic effects of TGF-ß and IL-lß on the beating rate of cultured cardiac myocytes. Molec Endocrinol 1992; in press.Google Scholar
  25. 25.
    Ignarro JJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30: 535–560.PubMedCrossRefGoogle Scholar
  26. 26.
    Roberts AB, Sporn MB. Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-ß. Cancer Surveys 1992; 14: 205–220.PubMedGoogle Scholar
  27. 27.
    Kilbourn RG, Griffith OW. Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 1992; 84: 827–831.PubMedCrossRefGoogle Scholar
  28. 28.
    Furukawa K-I, Ohshima N, Tawada-Iwata Y, et al. Cyclic GMP stimulates Na+/Ca2+ exchange in vascular smooth muscle cells in primary culture. J Biol Chem 1991; 266: 12337–12341.PubMedGoogle Scholar
  29. 29.
    Méry PF, Lohmann SM, Walter U, et al: Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci U S A 1991; 88: 1197–1201.PubMedCrossRefGoogle Scholar
  30. 30.
    Stamler JS, Simon DI, Osborne JA, et al. S-Nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A 1992; 89: 444–48.PubMedCrossRefGoogle Scholar
  31. 31.
    Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989; 13: 1637–1652PubMedCrossRefGoogle Scholar
  32. 32.
    Vukicevic S, Kleinman H, Luyten FP, et al. Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res 1992; in press.Google Scholar
  33. 33.
    Eddy LJ, Goeddel DV, Wong GHW. Tumor necrosis factor-α pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 1992; 184: 1056–1059.PubMedCrossRefGoogle Scholar
  34. 34.
    Brown JM, Grosso MA, Terada LS, et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts Proc Natl Acad Sci USA 1989; 86: 2516–2520.Google Scholar
  35. 35.
    Brown JM, White CW, Terada LS, et al. Interleukin-1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci USA 1990; 87: 5026–5030.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Anita B. Roberts
  • Michael B. Sporn

There are no affiliations available

Personalised recommendations